Massive upside: 8 largecap stocks set for up to 35% gains in 2026 - Add to Cart!

Analyst forecasts offer more than just numbers — they provide a strategic view of future market potential. For investors seeking the next big opportunity, a closer examination of BSE large-cap stocks highlights some promising contenders.Based on consensus estimates from Trendlyne, several large-cap stocks are projected to deliver strong returns over the next 12 months. This anticipated “upside” represents the average expected gain over the coming year, providing a data-driven benchmark for investors targeting high-potential large-cap opportunities. In this analysis, we spotlight eight standout large-cap stocks expected to deliver gains in the range of 20% to 35% in the year ahead. Our selection includes only companies that reported positive growth in net revenue and profit on a sequential basis in the latest September quarter.

Eternal is trading at Rs 284 at present. Based on analyst estimates, the target price stands at Rs 381, suggesting a potential upside of 34%. Of the 31 analysts covering the stock, the overall consensus is Buy.

The stock is currently priced at Rs 4,418. Analysts expect it to reach a target of Rs 5,672, translating into an upside potential of 28.4%. The consensus rating from 20 analysts is Buy.

Swiggy is trading at Rs 387. According to analyst estimates, the target price is Rs 495, implying an upside of 27.9%. Out of 25 analysts tracking the stock, the consensus view is Buy.

Currently trading at Rs 2,866, Waaree Energies has an analyst target price of Rs 3,530, suggesting a potential upside of 23.2%. Among the 11 analysts covering the stock, the consensus rating is Buy.

Apollo Hospitals is trading at Rs 7,130. Analysts have pegged the target price at Rs 8,669, indicating an upside potential of 21.6%. Of the 29 analysts following the stock, the consensus rating is Strong Buy.

The stock is currently valued at Rs 2,203. With a target price of Rs 2,677 set by analysts, the upside potential stands at 21.5%. The consensus recommendation from 18 analysts is Buy.

Max Healthcare is trading at Rs 1,063. Analyst estimates place the target price at Rs 1,267, implying an upside of 19.3%. Among 26 analysts covering the stock, the consensus rating remains Buy.